Potential of 18 F-FDG-PET as a valuable adjunct to clinical and response assessment in rheumatoid arthritis and seronegative spondyloarthropathies

Table 4 Response details in patients with rheumatoid arthritis: Fluorodeoxyglucose positron emission tomography vs clinical assessment

Sr. No.	No. of joints involved	Clinical assessment	% change in SUVmax
1	10	Mixed symptoms	Knee = 64% ↓
			Ankle = no change
			Wrist = 51.7% ↑
			Elbow = 47% ↓
2	4	Progressive disease	Knee = 44% ↑
			Ankle = 33% ↑
3	2	Improvement	Wrists = 62% ↓
4	6	Improvement	Ankle = 23% ↓
			Wrist = 45.2% ↓
5	4	Improvement	Wrist = 73 % ↓
			SJH* = 34% ↓
6	6	Improvement	Ankle = 43.3% ↓
			Wrists = 23 % ↓
			SJF* = 24.5% ↓
7		No response	No change
8		No response	No change
9	2	Progressive disease	Wrists = 48% ↑

SUVmax: Maximum standardized uptake value; SJF: Small joints of foot; SJH: Small joints of hand.